Sight Sciences Inc
$ 7.47
5.36%
07 Aug - close price
- Market Cap 411,507,000 USD
- Current Price $ 7.47
- High / Low $ 7.60 / 7.03
- Stock P/E N/A
- Book Value 0.97
- EPS -0.58
- Next Earning Report f
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.14 %
- ROE -0.48 %
- 52 Week High 9.24
- 52 Week Low 3.19
About
Sight Sciences Inc. (SGHT) is an innovative medical technology company specializing in the advancement of treatments for ocular diseases, with a particular emphasis on glaucoma management through both surgical and non-surgical approaches. The company’s diverse product portfolio, supported by a robust intellectual property framework, positions it favorably as demand for minimally invasive ophthalmic therapies escalates. By focusing on enhancing patient outcomes and refining its distribution network, Sight Sciences is set to capture significant market share in the evolving healthcare landscape, making it a noteworthy opportunity for institutional investors seeking growth in the medical technology sector.
Analyst Target Price
$8.60
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-06 | 2026-03-04 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-03-05 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-03-07 | 2023-11-07 |
| Reported EPS | -0.08 | -0.24 | -0.08 | -0.16 | -0.23 | -0.28 | -0.23 | -0.22 | -0.25 | -0.29 | -0.22 | -0.27 |
| Estimated EPS | -0.15 | -0.2 | -0.1529 | -0.26 | -0.25 | -0.23 | -0.176 | -0.21 | -0.3 | -0.28 | -0.32 | -0.33 |
| Surprise | 0.07 | -0.04 | 0.0729 | 0.1 | 0.02 | -0.05 | -0.054 | -0.01 | 0.05 | -0.01 | 0.1 | 0.06 |
| Surprise Percentage | 46.6667% | -20% | 47.6782% | 38.4615% | 8% | -21.7391% | -30.6818% | -4.7619% | 16.6667% | -3.5714% | 31.25% | 18.1818% |
Next Quarterly Earnings
| Aug 2026 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SGHT
2026-08-06 20:11:23
Sight Sciences Inc. (SGHT) reported strong Q2 2026 earnings, featuring a 20% year-over-year increase in total revenue to $23.4 million, marking its strongest quarterly growth in three years. The company also saw significant improvement in its interventional dry eye revenue, which nearly doubled, and reduced its net loss by 63%. SGHT raised its full-year 2026 revenue guidance to $88 million to $92 million and secured a major market access win with Aetna, adding 25 million covered lives for its procedures.
2026-08-06 15:42:08
UBS has increased its price target for Sight Sciences (SGHT) to $8 from $7, while reiterating a Buy rating on the stock. This adjustment follows Sight Sciences' Q2 2026 earnings call and news of FDA 510(k) clearance for its OMNI Ultra Surgical System. The company specializes in eyecare technology, focusing on surgical and non-surgical treatments for eye diseases.
2026-08-06 09:10:04
Sight Sciences reported strong Q2 revenue growth of 20% year-over-year, driven by gains in its interventional glaucoma and dry eye businesses, leading to a raised full-year revenue outlook. The company also reduced operating expenses and cash usage, with a net loss narrowing significantly. Key drivers included increased adoption of its TearCare platform and expanded payer coverage for OMNI procedures, alongside preparations for the launch of OMNI Ultra.
2026-08-06 04:14:34
Sight Sciences, Inc. reported strong financial results for Q2 2026, with revenue increasing by 20 percent to $23.4 million and a significant reduction in net loss. The company raised its full-year 2026 revenue guidance to $88 million to $92 million, driven by growth in both Interventional Glaucoma and Interventional Dry Eye segments. This positive outlook follows the recent FDA 510(k) clearance of its OMNI Ultra Surgical System.
2026-08-06 01:14:34
Sight Sciences reported a strong Q2 2026 with revenue increasing 20% year-over-year to $23.4 million, its fastest growth since 2023, and a narrowed net loss. The company raised its full-year 2026 revenue guidance to $88 million-$92 million and lowered adjusted operating expense guidance. Despite the positive financial results and improved margins, the stock fell, suggesting investors had higher expectations for sustained profitability.
2026-08-06 00:14:34
Sight Sciences, Inc. has released its earnings summary for the quarter that ended on June 30. The report, provided by Refinitiv, gives an overview of the company's financial performance during this period.
